GLP1R and X-linked cone dysfunction syndrome with myopia: Early open-label studies with relatively small sample sizes using GLP-1R agonists such as liraglutide (122, 123) and dulaglutide (124) show promising effects in reducing binge episodes and weight in BED, but further research is needed to confirm their benefits across diverse populations.